NCT07739992 Dose Optimization Study of Acute Intermittent Hypoxia in Spinal Cord Injury
| NCT ID | NCT07739992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Milap Sandhu |
| Condition | Spinal Cord Injuries (SCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-07-27 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-07-27 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate how different doses of acute intermittent hypoxia (AIH) affect lower-limb strength, reaction time, and responsiveness in individuals with spinal cord injury (SCI). The objective is to identify the dose that most effectively improves motor output while also examining parameters that may account for variability in response.
Eligibility Criteria
Inclusion Criteria: * Chronic Spinal Cord Injury (\>6 months) * Motor incomplete SCI classified as AIS C or D * Volitional ankle plantarflexion strength in at least one leg Exclusion Criteria: * Uncontrolled hypertension (outside 140/90 and 90/60) * Concurrent medical illness * Traumatic brain injury * Cardiovascular complications * Pulmonary complications * Metabolic dysfunction * Continued use of anti-spasticity medications * Previously diagnosed obstructive sleep apnea
Contact & Investigator
Milap Sandhu, PT, PhD
PRINCIPAL INVESTIGATOR
Shirley Ryan AbilityLab
Frequently Asked Questions
Who can join the NCT07739992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spinal Cord Injuries (SCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07739992 currently recruiting?
Yes, NCT07739992 is actively recruiting participants. Contact the research team at msandhu@sralab.org for enrollment information.
Where is the NCT07739992 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07739992 clinical trial?
NCT07739992 is sponsored by Milap Sandhu. The principal investigator is Milap Sandhu, PT, PhD at Shirley Ryan AbilityLab. The trial plans to enroll 40 participants.